Abstract:In this study the three-dimensional (3-D) model of the ligand-binding domain (V106-P322) of human interleukin-6 receptor (hIL-6 R) was constructed by computer-guided homology modeling technique using the crystal structure of the ligand-binding domain (K52-L251) of human growth hormone receptor (hGHR) as templet. Furthermore, the active binding region of the 3-D model of hIL-6R with the ligand (hIL-6) was predicted. In light of the structural characteristics of the active region, a hydrophobic pocket shielded by two hydrophilic residues (E115 and E505) of the region was identified by a combination of molecular modelling and the site-directed or double-site mutation of the twelve crucial residues in the ligand-binding domain of hIL-6R (V106-P322). We observed and analyzed the effects of these mutants on the spatial conformation of the pocket-like region of hIL-6 R. The results indicated that any site-directed mutation of the five Cys residues (four conservative Cys residues: Cys121, Cys132, Cys165, Cys176; near membrane Cys residue: Cys193) or each double-site mutation of the five residues in WSEWS motif of hIL-6R (V106-P322) makes the corresponding spatial conformation of the pocket region block the linkage between hIL-6 R and hIL-6. However, the influence of the site-directed mutation of Cys211 and Cys277 individually on the conformation of the pocket region benefits the interaction between hIL-6R and hIL-6. Our study suggests that the predicted hydrophobic pocket in the 3-D model of hIL-6R (V106-P322) is the critical molecular basis for the binding of hIL-6R with its ligand, and the active pocket may be used as a target for designing small hIL-6R-inhibiting molecules in our further study.

Establishment of M1 cell model applicable to screening human IL-6 receptor antagonists

Structure-based Virtual Screening and Characterization of a Novel IL-6 Antagonistic Compound from Synthetic Compound Database

A Novel Hil-6 Antagonist Peptide from Computer-Aided Design Contributes to Suppression of Apoptosis in M1 Cells

Searching Interleukin 6 Antagonists by Screening Random Peptide Libraries

Comparison of IL-6-activated-nuclear Factors in M1 and 7TD1 Cells

Advances in Structural Base of Interaction Between Hil-6 and Its Receptor and Antagonist of Hil-6

Establishment and Application of High Throughput Screening Model for H1R Antagonists

Unveiling novel insights into human IL-6 - IL-6R interaction sites through 3D computer-guided docking and systematic site mutagenesis

The Rational Designed Antagonist Derived from the Complex Structure of Interleukin-6 and Its Receptor Affectively Blocking Interleukin-6 Might Be a Promising Treatment in Multiple Myeloma

[Establishment of a Cell Model Targeted to NFAT Signal Transduction Pathway for Preliminary Screening of FK506-like Immunosuppressants].

Establishment of a CaCC-based Cell Model and Method for High-throughput Screening of M3 Receptor Drugs

Establishment of A Cell Model Based on Fkbp12 Dimerization for Screening of Fk506-Like Neurotrophic Small Molecular Compounds

Functional Identification of the Stable Transfection C5ar Cell Line Molt-4

The Inhibitory Activity of a Novel Small-Molecule Inhibitor of IL-6 Signalling in Vitro

High Throughput Screening Method of Identifying Agonist for Muscarinic Receptor

Establishment of Immunoradio Assay for Detecting Human IL-6 and Its Application

Three-dimensional Structure and Function Study on the Active Region in the Extracellular Ligand-Binding Domain of Human IL-6 Receptor

The design of antagonist peptide of hIL-6 based on the binding epitope of hIL-6 by computer-aided molecular modeling.

Development of a cell-based qualitative assay for detection of neutralizing anti-human interleukin-1 receptor antagonist (hIL-1Ra) antibodies in rats.

PC12 Cells Express IL-1 Receptor Type I and Response to IL-1β Stimulation

Function and molecular modeling of the interaction between human interleukin 6 and its HNK-1 oligosaccharide ligands